Biognosis buys Abion to serve as research & development centre:
This article was originally published in Clinica
Biognosis has bought the assets of Abion, of Julich, Germany, and formed a new German subsidiary, Biognosis. The UK company, which is developing serology tests for infectious diseases, says Abion's technology supports its development of high speed, quantitative immunoassays. The German subsidiary will serve as Biognosis' R&D centre. High Wycombe-based Biognosis, which is privately-funded, plans to spend DM10 million ($5.6 million) on development projects over the next four years. The first are expected in mid-1999.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.